Literature DB >> 8452184

Overview of the pharmacokinetics of fleroxacin.

C H Nightingale1.   

Abstract

The pharmacokinetic properties of fleroxacin in relation to other quinolones are presented. Fleroxacin, like all quinolones, is well absorbed, reaching peak concentrations within 2 hours. Interactions with Ca2+ and Al3+ are minimal and possibly of little clinical importance. The drug is eliminated via filtration in the kidney. It is therefore sensitive to changes in renal function. Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations. Aside from the modest effect of metals on its absorption, fleroxacin does not interact/compete with substances oxidized in the liver, such as theophylline, and drug interactions are minimal. Its long serum half-life (8-12 hours) allows once-a-day dosing. This feature, along with its modest drug interactions, makes fleroxacin an attractive quinolone, at least with respect to its pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452184

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

Authors:  D Beauchamp; G Laurent; L Grenier; P Gourde; J Zanen; J A Heuson-Stiennon; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Authors:  J Schrenzel; F Cerruti; M Herrmann; T Leemann; E Weidekamm; R Portmann; B Hirschel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

3.  Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.

Authors:  D E Uehlinger; F Schaedeli; M Kinzig; F Sörgel; F J Frey
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

4.  In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.

Authors:  M Araque; E Velazco
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 5.  Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones.

Authors:  Javier P Gisbert
Journal:  Molecules       Date:  2020-11-02       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.